Improving solubility and refolding efficiency of human VHs by a novel mutational approach

The antibody VH domains of camelids tend to be soluble and to resist aggregation, in contrast to human VH domains. For immunotherapy, attempts have therefore been made to improve the properties of human VHs by camelization of a small set of framework residues. Here, we have identified through sequen...

Full description

Saved in:
Bibliographic Details
Published inProtein engineering, design and selection Vol. 19; no. 11; pp. 503 - 509
Main Authors Tanha, Jamshid, Nguyen, Thanh-Dung, Ng, Andy, Ryan, Shannon, Ni, Feng, MacKenzie, Roger
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.11.2006
Oxford Publishing Limited (England)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The antibody VH domains of camelids tend to be soluble and to resist aggregation, in contrast to human VH domains. For immunotherapy, attempts have therefore been made to improve the properties of human VHs by camelization of a small set of framework residues. Here, we have identified through sequence comparison of well-folded llama VH domains an alternative set of residues (not typically camelid) for mutation. Thus, the solubility and thermal refolding efficiency of a typical human VH, derived from the human antibody BT32/A6, were improved by introduction of two mutations in framework region (FR) 1 and 4 to generate BT32/A6.L1. Three more mutations in FR3 of BT32/A6.L1 further improved the thermal refolding efficiency while retaining solubility and cooperative melting profiles. To demonstrate practical utility, BT32/A6.L1 was used to construct a phage display library from which were isolated human VHs with good antigen binding activity and solubility. The engineered human VH domains described here may be useful for immunotherapy, due to their expected low immunogenicity, and in applications involving transient high temperatures, due to their efficient refolding after thermal denaturation.
Bibliography:ark:/67375/HXZ-XMJD2W0H-V
istex:DCE3E0183AE50F36573C265F31DEC12A7ED0FFC9
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1741-0126
1741-0134
DOI:10.1093/protein/gzl037